For Immediate Release

Chicago, IL July 10, 2012 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Qiagen (QGEN), Bristol-Myers Squibb Co. (BMY), Eli Lilly & Co. (LLY), Quest Diagnostics (DGX) and Myriad Genetics (MYGN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Mondays Analyst Blog:

FDA Approves Qiagens KRAS Test

Molecular diagnostics solutions provider, Qiagen (QGEN) recently got the nod of the U.S. Food and Drug Administration (FDA) to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test), which helps in determining the responsiveness of the metastatic colorectal cancer patients to the drug Erbitux (cetuximab). Qiagen considers this FDA approval of the therascreen KRAS test as a major breakthrough in the companys international expansion of its Personalized Healthcare franchise that comprises a huge portfolio of molecular companion diagnostics to guide treatments in oncology.

The drug Erbitux is an epidermal growth factor receptor (:EGFR) inhibitor and is used to treat colon and rectum cancer. It is also beneficial for head and neck cancer treatment. Currently, this drug is marketed in the U.S. by Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY).

Excerpt from:
The Zacks Analyst Blog Highlights: Qiagen, Bristol-Myers Squibb, Eli Lilly, Quest Diagnostics and Myriad Genetics

Comments are closed.